Studying synergistic effects of temozolomide and vistusertib in glioblastoma cells
Glioblastoma (GBM) is a highly aggressive malignant brain tumour with an exceptionally poor prognosis, largely driven by intrinsic resistance to standard-of-care chemotherapy with temozolomide (TMZ). Aberrant activation of the mechanistic target of rapamycin complex 2 (mTORC2) signalling plays a crucial role in GBM cel...